Evidence map›Paper›PMID 37737200›Full record

ArticleDiagnostic pathology2023

MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.

Go Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, Naohiro Uraoka, Takafumi Fukui, Aya Kido, Narutaka Katsuya, Akira Ishikawa, Takashi Babasaki, Yohei Sekino and 4 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.Journal of experimental & clinical cancer research : CR · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Go KobayashiDepartment of Pathology, Kure-Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Hiroshima, Japan.
Tetsutaro HayashiDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, -2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Kazuhiro SentaniDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. kzsentani@hiroshima-u.ac.jp.
Naohiro UraokaDepartment of Pathology, Kure-Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Hiroshima, Japan.
Takafumi FukuiDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Aya KidoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Narutaka KatsuyaDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Akira IshikawaDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takashi BabasakiDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, -2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Yohei SekinoDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, -2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroyuki NoseDepartment of Urology, Kure-Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Hiroshima, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
Nobuyuki HinataDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, -2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Naohide OueDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima University · JPKure Kyosai Hospital · JPHiroshima University Hospital · JP

Funding

Japan Society for the Promotion of Science 22K06959
6 · The paper itself

Abstract

backgroundWe previously reported Minichromosome maintenance 4 (MCM4) overexpression in gastric cancer. However, the clinicopathological significance of MCM4 in urothelial carcinoma (UC) has not been investigated. To clarify the clinicopathological significance of MCM4 in UC, we investigated MCM4 expression with immunohistochemistry (IHC).

methodsWe analyzed the expression and distribution of MCM4 in 124 upper tract urothelial carcinoma (UTUC) samples by IHC. Additionally, using 108 urine samples, we analyzed MCM4 Immunocytochemistry (ICC) expression in urine cytology.

resultsIn normal urothelium, MCM4 expression was weak or absent. Meanwhile, the strong nuclear expression of MCM4 was observed in UTUC tissues, and it was detected in 77 (62%) of a total of 124 UTUC cases. MCM4-positive UTUC cases were associated with nodular/flat morphology, high grade, high T stage, and poor prognosis. Moreover, MCM4 expression was significantly higher in the invasive front than in the tumor surface. Similar results were also obtained in TCGA bladder cancer cohort. Additionally, MCM4 expression was associated with high expression of Ki-67, HER2, EGFR, and p53 in UTUC. Among representative cancer-related molecules, MCM4 had an independent predictive value for progression-free survival and high-grade UC. ICC for MCM4 was also performed on urine cytology slides and showed that the nuclear expression of MCM4 was more frequently found in UC cells than in non-neoplastic cells. The diagnostic accuracy of urine cytology was improved by combining MCM4 immunostaining with cytology.

conclusionThese results suggest that MCM4 might be a useful predictive biomarker for high-grade histology, tumor progression and poor prognosis in UC. Moreover, ICC for MCM4 might be helpful for UC detection as additional markers in the cytomorphology-based diagnosis.

Indexed as

Carcinoma, Transitional CellStomach NeoplasmsUrinary Bladder NeoplasmsHumansMinichromosome Maintenance Complex Component 4Progression-Free SurvivalUrotheliumMCM4 protein, humanMinichromosome Maintenance Complex Component 4Clinicopathological significanceImmunocytochemistryImmunohistochemistryMCM4Urine cytologyUrothelial carcinoma

Identifiers

PMID37737200
PMCPMC10515259
OpenAlexW4386945500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.